Suppr超能文献

NMDA 受体阻断改善帕金森病非人灵长类动物丘脑底核神经元放电异常。

NMDA receptor blockade ameliorates abnormalities of spike firing of subthalamic nucleus neurons in a parkinsonian nonhuman primate.

机构信息

Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia.

Yerkes National Primate Research Center, Emory University, Atlanta, Georgia.

出版信息

J Neurosci Res. 2018 Jul;96(7):1324-1335. doi: 10.1002/jnr.24230. Epub 2018 Mar 25.

Abstract

N-methyl-D-aspartate receptors (NMDARs) are ion channels comprising tetrameric assemblies of GluN1 and GluN2 receptor subunits that mediate excitatory neurotransmission in the central nervous system. Of the four different GluN2 subunits, the GluN2D subunit-containing NMDARs have been suggested as a target for antiparkinsonian therapy because of their expression pattern in some of the basal ganglia nuclei that show abnormal firing patterns in the parkinsonian state, specifically the subthalamic nucleus (STN). In this study, we demonstrate that blockade of NMDARs altered spike firing in the STN in a male nonhuman primate that had been rendered parkinsonian by treatment with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. In accompanying experiments in male rodents, we found that GluN2D-NMDAR expression in the STN was reduced in acutely or chronically dopamine-depleted animals. Taken together, our data suggest that blockade of NMDARs in the STN may be a viable antiparkinsonian strategy, but that the ultimate success of this approach may be complicated by parkinsonism-associated changes in NMDAR expression in the STN.

摘要

N-甲基-D-天冬氨酸受体(NMDAR)是由 GluN1 和 GluN2 受体亚基组成的四聚体离子通道,在中枢神经系统中介导兴奋性神经传递。在四种不同的 GluN2 亚基中,含有 GluN2D 亚基的 NMDAR 被认为是抗帕金森病治疗的靶点,因为它们在一些基底神经节核中表达,这些核在帕金森病状态下表现出异常的放电模式,特别是丘脑底核(STN)。在这项研究中,我们证明了在雄性非人类灵长类动物中,用神经毒素 1-甲基-4-苯基-1,2,3,6-四氢吡啶处理使其帕金森病后,阻断 NMDAR 会改变 STN 中的尖峰放电。在雄性啮齿动物的伴随实验中,我们发现急性或慢性多巴胺耗竭动物的 STN 中 GluN2D-NMDAR 表达减少。总之,我们的数据表明,阻断 STN 中的 NMDAR 可能是一种可行的抗帕金森病策略,但由于帕金森病相关的 STN 中 NMDAR 表达的变化,这种方法的最终成功可能会变得复杂。

相似文献

2
NMDA receptors are altered in the substantia nigra pars reticulata and their blockade ameliorates motor deficits in experimental parkinsonism.
Neuropharmacology. 2020 Sep 1;174:108136. doi: 10.1016/j.neuropharm.2020.108136. Epub 2020 May 29.
3
NMDA Receptors Containing the GluN2D Subunit Control Neuronal Function in the Subthalamic Nucleus.
J Neurosci. 2015 Dec 2;35(48):15971-83. doi: 10.1523/JNEUROSCI.1702-15.2015.
4
Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
J Neurosurg. 2015 Dec;123(6):1383-93. doi: 10.3171/2014.10.JNS141570. Epub 2015 May 1.
7
Allosteric modulation of NMDA receptors alters neurotransmission in the striatum of a mouse model of Parkinson's disease.
Exp Neurol. 2014 May;255:154-60. doi: 10.1016/j.expneurol.2014.03.001. Epub 2014 Mar 12.
8
Subthalamo-pallidal interactions underlying parkinsonian neuronal oscillations in the primate basal ganglia.
Eur J Neurosci. 2011 Nov;34(9):1470-84. doi: 10.1111/j.1460-9568.2011.07865.x.
9
Localization and function of dopamine receptors in the subthalamic nucleus of normal and parkinsonian monkeys.
J Neurophysiol. 2014 Jul 15;112(2):467-79. doi: 10.1152/jn.00849.2013. Epub 2014 Apr 23.
10
NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats.
Neuropharmacology. 2014 Oct;85:198-205. doi: 10.1016/j.neuropharm.2014.05.024. Epub 2014 May 24.

引用本文的文献

1
Spatiotemporal differential regulation of extrasynaptic GluN2B receptor subunits and PSA-NCAM in brain aging and Alzheimer's disease.
Front Neurosci. 2025 Aug 29;19:1649625. doi: 10.3389/fnins.2025.1649625. eCollection 2025.
3
Mechanisms of Action Underlying Conductance-Modifying Positive Allosteric Modulators of the NMDA Receptor.
Mol Pharmacol. 2024 Nov 18;106(6):334-353. doi: 10.1124/molpharm.124.001019.
5
Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry.
Neuropsychopharmacology. 2024 Jan;49(1):51-66. doi: 10.1038/s41386-023-01614-3. Epub 2023 Jun 27.
7
Doxorubicin induces dysregulation of AMPA receptor and impairs hippocampal synaptic plasticity leading to learning and memory deficits.
Heliyon. 2021 Jul 1;7(7):e07456. doi: 10.1016/j.heliyon.2021.e07456. eCollection 2021 Jul.
8
Building a Bridge Between NMDAR-Mediated Excitotoxicity and Mitochondrial Dysfunction in Chronic and Acute Diseases.
Cell Mol Neurobiol. 2021 Oct;41(7):1413-1430. doi: 10.1007/s10571-020-00924-0. Epub 2020 Jul 22.
9
Battery-free, lightweight, injectable microsystem for in vivo wireless pharmacology and optogenetics.
Proc Natl Acad Sci U S A. 2019 Oct 22;116(43):21427-21437. doi: 10.1073/pnas.1909850116. Epub 2019 Oct 10.
10
Functional and pharmacological properties of triheteromeric GluN1/2B/2D NMDA receptors.
J Physiol. 2019 Nov;597(22):5495-5514. doi: 10.1113/JP278168. Epub 2019 Nov 2.

本文引用的文献

4
Loss of Hyperdirect Pathway Cortico-Subthalamic Inputs Following Degeneration of Midbrain Dopamine Neurons.
Neuron. 2017 Sep 13;95(6):1306-1318.e5. doi: 10.1016/j.neuron.2017.08.038.
5
Loss and remodeling of striatal dendritic spines in Parkinson's disease: from homeostasis to maladaptive plasticity?
J Neural Transm (Vienna). 2018 Mar;125(3):431-447. doi: 10.1007/s00702-017-1735-6. Epub 2017 May 24.
7
Molecular Mechanism of Disease-Associated Mutations in the Pre-M1 Helix of NMDA Receptors and Potential Rescue Pharmacology.
PLoS Genet. 2017 Jan 17;13(1):e1006536. doi: 10.1371/journal.pgen.1006536. eCollection 2017 Jan.
9
Mechanistic Insight into NMDA Receptor Dysregulation by Rare Variants in the GluN2A and GluN2B Agonist Binding Domains.
Am J Hum Genet. 2016 Dec 1;99(6):1261-1280. doi: 10.1016/j.ajhg.2016.10.002. Epub 2016 Nov 10.
10
Neuronal firing patterns outweigh circuitry oscillations in parkinsonian motor control.
J Clin Invest. 2016 Dec 1;126(12):4516-4526. doi: 10.1172/JCI88170. Epub 2016 Oct 31.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验